Categories: News

Genalyte Announces Oversubscribed $50 Million Financing Round to Expand Testing Menu and Deploy Platform

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ — Genalyte, a leading diagnostics and analytics company, announced today the closure of $50 million in financing.  Genalyte’s Maverick™ Diagnostic System (MDS) uses silicon chip based photonic ring resonance technology to perform multiple, simultaneous, rapid tests on a small volume of whole blood or serum in twenty minutes.

“We are energized by the very enthusiastic response from Investors for this latest round of funding,” said CEO Ashraf Hanna.  “Genalyte is uniquely positioned to improve the laboratory diagnostic and analytic space.  We’ve demonstrated the strength of our technology in our EUA authorized SARS-CoV-2 Multi-Antigen Serology Panel, which is able to measure 26 different antibodies from one drop of blood.  Independent tests by the Mayo Clinic, Scripps, and Northshore Healthcare have consistently verified the platform’s industry leading capabilities.”  

The financing round was led by Verily, an Alphabet company, and included current major investors Provenio Capital, Redmile, Khosla Ventures, HBM Partners, Samsara and others.

Andy Conrad, CEO and founder of Verily has been nominated to Genalyte’s board of directors.  “Verily and Genalyte share a common vision of empowering physicians and patients with timely insights to improve outcomes and lower the cost of care,” said Andrew Conrad.  “I look forward to working with Genalyte as they continue to innovate technology to advance rapid diagnostics and analytics.”

The company intends to utilize the funding to expand the Maverick test menu and rapidly deploy the Maverick platform in clinical and retail settings.  

About Genalyte: Genalyte is a healthcare diagnostics and analytics company that improves patient outcomes and lowers cost with real-time results for physicians and patients. Genalyte delivers rapid, actionable results to doctors through decentralized laboratory testing. For more information, please visit www.genalyte.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/genalyte-announces-oversubscribed-50-million-financing-round-to-expand-testing-menu-and-deploy-platform-301205549.html

SOURCE Genalyte Inc

Staff

Recent Posts

Aktiia secures $42 million in Series B funding round and rebrands to Hilo

With fresh funding round, the health tech pioneer continues to work toward managing the world's…

2 hours ago

RaySearch releases RayStation v2025

STOCKHOLM, May 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the launch of RayStation®*…

2 hours ago

Cosmo Announces EU MDR Certification for Endovision’s Cerebro, expanding its real-time AI ecosystem

Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision…

6 hours ago

America’s Poison Centers: Using Trusted Sources for Your Critical Health Information

Poison Help (1-800-222-1222/ PoisonHelp.org) provides 24/7 free, expert advice from one of 53 nationally accredited,…

14 hours ago

Olympus Demonstrates New AI Endoscopy Solution at DDW®

The OLYSENSE Platform Aims to Strengthen Clinical Decision-Making by Leveraging Cloud-based Connectivity and AI Computing…

14 hours ago